Can high-intensity chemotherapy improve breast cancer?

University of Heidelberg, Germany, Dr. ManfredHensel that previous studies found that treatment of P53 and Her2/neu conventional prognostic factors. Moreover, the high risk associated with axillary lymph node metastasis and poor prognosis in patients with conventional chemotherapy. To this end, researchers began to study since 1992, autologous blood stem cell transplantation-assisted high-intensity chemotherapy treatment.

The researchers selected the commonly used clinical parameters such as tumor size, axillary lymph node metastases, and several other commonly used laboratory parameters, including hormone receptor levels and tumor grade, to evaluate the prognosis. Also analyzed by immunohistochemistry of tumor molecular markers, it is surprised to is that the predictive value of conventional clinical parameters less than the modern molecular targets.

Dr. Hensel, multivariate analysis showed that high-dose chemotherapy is the best prognostic factors and Her2/neu overexpression of P53, the relative risk was 6.06 and 3.86.

Dr. Hensel, may be used in future high-intensity chemotherapy, P53 and Her2/neu overexpression in patients, while other patients may need other treatment options such as: antibody therapy, cancer vaccines and cell therapy.